Genomic approaches were applied to demonstrate that c-Myc regulates radioresistance through transcriptional activation of Chk1 and Chk2 by direct binding to their gene promoters in nasopharyngeal carcinoma cells, revealing a potential therapeutic strategy in reduction of radioresistance through blockade of the c-Myc-Chk1/Chk2 pathway [32]. This evidence concerns the gene MYC and nasopharyngeal carcinoma.